TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telephone Assessment and Skill-Building Intervention for Stroke Caregivers
Brief Summary: The purpose of this study is to test the efficacy of the revised Telephone Assessment and Skill-Building Kit (TASK II) compared with an Information, Support, and Referral (ISR) intervention in family caregivers of stroke survivors. We will also test if TASK II intervention effects on primary outcomes (depressive symptoms, caregiving-related negative life changes, unhealthy days) are mediated through effects on secondary outcomes (task difficulty, optimism, threat appraisal). Comparative costs and outcomes for the TASK II and ISR interventions will also be explored.


Options:
A: Arm Label: Standard Care, Organized Discharge; Type: PLACEBO_COMPARATOR; Interventions: Other: Video Arm | Arm Label: Video Arm, Standard Discharge; Type: EXPERIMENTAL; Interventions: Other: Video Arm | Intervention Type: OTHER; Name: Video Arm; Assigned to Arm(s): Standard Care, Organized Discharge, Video Arm, Standard Discharge
B: Arm Label: Telephone Assessment and Skill-Building Kit (TASK II); Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Assessment and Skill-Building Kit (TASK II) | Arm Label: Information, Support, and Referral (ISR); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information, Support, and Referral (ISR) | Intervention Type: BEHAVIORAL; Name: Telephone Assessment and Skill-Building Kit (TASK II); Assigned to Arm(s): Telephone Assessment and Skill-Building Kit (TASK II) | Intervention Type: BEHAVIORAL; Name: Information, Support, and Referral (ISR); Assigned to Arm(s): Information, Support, and Referral (ISR)
C: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Instruction in physical training program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Instruction in physical training program; Assigned to Arm(s): Intervention arm
D: Arm Label: optimised follow-up; Type: OTHER; Interventions: Other: optimised follow-up | Arm Label: typical follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: optimised follow-up; Assigned to Arm(s): optimised follow-up

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial on the Effect of Guided Imagery and Progressive Muscle Relaxation for the Management of Pain, Stress, Anxiety and Depression as a Means to Improve the Psychological Well-being and the Quality of Life for Patients With Breast and Prostate Cancer
Brief Summary: The purpose of this study is to determine whether Guided Imagery and Progressive Muscle Relaxation techniques are effective in the management of pain, fatigue, nausea-vomit, anxiety and depression in patients with either prostate or breast cancer.

This study includes a total of 200 patients with prostate and breast cancer randomly assigned to either a control or intervention group.

The intervention group received in total 4 sessions of Guided Imagery (protocol floating on a cloud) and Progressive Muscle Relaxation (breathing exercises and use of 11 groups of muscle progressively tensing and relaxing).

Measurements included the assessment of pain, fatigue, nausea-vomit, depression, anxiety and quality of life. Additionally, saliva samples were collected prior and after the sessions as to assess saliva cortisol and saliva α-amylase.

The same measurements were received by the patients of the control group as to allow comparisons.


Options:
A: Arm Label: Compassion; Type: EXPERIMENTAL; Interventions: Behavioral: CBCT | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Other: TAU | Intervention Type: BEHAVIORAL; Name: CBCT; Assigned to Arm(s): Compassion | Intervention Type: OTHER; Name: TAU; Assigned to Arm(s): Treatment as usual
B: Arm Label: Mindfulness-Based Cognitive Therapy (MBCT); Type: EXPERIMENTAL; Interventions: Other: Mindfulness-Based Cognitive Therapy | Arm Label: Waitlist control group; Type: OTHER; Interventions: Other: Waitlist | Intervention Type: OTHER; Name: Mindfulness-Based Cognitive Therapy; Assigned to Arm(s): Mindfulness-Based Cognitive Therapy (MBCT) | Intervention Type: OTHER; Name: Waitlist; Assigned to Arm(s): Waitlist control group
C: Arm Label: Nurse-led care; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led care, Behavioral: Routine care | Arm Label: Routine care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Routine care | Intervention Type: BEHAVIORAL; Name: Nurse-led care; Assigned to Arm(s): Nurse-led care | Intervention Type: BEHAVIORAL; Name: Routine care; Assigned to Arm(s): Nurse-led care, Routine care
D: Arm Label: Guided Imagery and Progressive Muscle Relaxation; Type: EXPERIMENTAL; Interventions: Other: Guided Imagery and Progressive Muscle Relaxation | Intervention Type: OTHER; Name: Guided Imagery and Progressive Muscle Relaxation; Assigned to Arm(s): Guided Imagery and Progressive Muscle Relaxation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Amphia Premature Infant Pain Study; Breast Milk vs Sucrose
Brief Summary: Last thirty years, many research was performed concerning pain in the newborn. These investigations showed us the negative effects of pain in the neonatal period. Our research concerns the choice of analgesics for the premature newborn during a heel lance. Newborns with a gestational age of 32-37 weeks are randomly assigned over three groups. They can receive breastfeeding, during the heel lance, a bottle with supplemental breast milk or sucrose.

The primary objective of the Amphia Premature Infant Pain study, is to investigate whether there is a difference in PIPP-scores in premature newborns who undergo a heel lance, receiving breast milk or sucrose. Our hypothesis is that the PIPP-score will be lower in newborns receiving breast milk compared to sucrose. And the investigators presume that breast feeding has the same analgesic effect as giving supplemental breast milk.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sucrose 24% oral solution | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: sterile water | Intervention Type: DRUG; Name: sucrose 24% oral solution; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sterile water; Assigned to Arm(s): 2
B: Arm Label: sucrose; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: supplemental breast milk; Type: ACTIVE_COMPARATOR; Interventions: Other: supplemental breast milk | Arm Label: Breast feeding; Type: ACTIVE_COMPARATOR; Interventions: Other: breast feeding | Intervention Type: OTHER; Name: breast feeding; Assigned to Arm(s): Breast feeding | Intervention Type: OTHER; Name: supplemental breast milk; Assigned to Arm(s): supplemental breast milk | Intervention Type: OTHER; Name: sucrose; Assigned to Arm(s): sucrose
C: Arm Label: Breastfeeding; Type: EXPERIMENTAL; Interventions: Other: Breastfeeding | Arm Label: 24% oral sucrose; Type: ACTIVE_COMPARATOR; Interventions: Drug: 24% oral sucrose | Intervention Type: OTHER; Name: Breastfeeding; Assigned to Arm(s): Breastfeeding | Intervention Type: DRUG; Name: 24% oral sucrose; Assigned to Arm(s): 24% oral sucrose
D: Arm Label: 0.1ml 24% sucrose concurrent opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 0.5ml 24% sucrose concurrent opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 1.0ml 24% sucrose concurrent opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 0.1ml 24% sucrose no opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 0.5ml 24% sucrose no opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 1.0ml 24% sucrose no opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Intervention Type: OTHER; Name: sucrose; Assigned to Arm(s): 0.1ml 24% sucrose concurrent opioids, 0.1ml 24% sucrose no opioids, 0.5ml 24% sucrose concurrent opioids, 0.5ml 24% sucrose no opioids, 1.0ml 24% sucrose concurrent opioids, 1.0ml 24% sucrose no opioids

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Amphia Premature Infant Pain Study; Breast Milk vs Sucrose
Brief Summary: Last thirty years, many research was performed concerning pain in the newborn. These investigations showed us the negative effects of pain in the neonatal period. Our research concerns the choice of analgesics for the premature newborn during a heel lance. Newborns with a gestational age of 32-37 weeks are randomly assigned over three groups. They can receive breastfeeding, during the heel lance, a bottle with supplemental breast milk or sucrose.

The primary objective of the Amphia Premature Infant Pain study, is to investigate whether there is a difference in PIPP-scores in premature newborns who undergo a heel lance, receiving breast milk or sucrose. Our hypothesis is that the PIPP-score will be lower in newborns receiving breast milk compared to sucrose. And the investigators presume that breast feeding has the same analgesic effect as giving supplemental breast milk.


Options:
A: Intervention Type: DRUG; Name: Sucrose solution 30%1 ml; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding; Assigned to Arm(s): N/A
B: N/A
C: Arm Label: Breast Milk; Type: ACTIVE_COMPARATOR; Interventions: Other: Breast Human Milk | Arm Label: 24 %Sucrose; Type: OTHER; Interventions: Other: 24 % Sucrose | Intervention Type: OTHER; Name: Breast Human Milk; Assigned to Arm(s): Breast Milk | Intervention Type: OTHER; Name: 24 % Sucrose; Assigned to Arm(s): 24 %Sucrose
D: Arm Label: sucrose; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: supplemental breast milk; Type: ACTIVE_COMPARATOR; Interventions: Other: supplemental breast milk | Arm Label: Breast feeding; Type: ACTIVE_COMPARATOR; Interventions: Other: breast feeding | Intervention Type: OTHER; Name: breast feeding; Assigned to Arm(s): Breast feeding | Intervention Type: OTHER; Name: supplemental breast milk; Assigned to Arm(s): supplemental breast milk | Intervention Type: OTHER; Name: sucrose; Assigned to Arm(s): sucrose

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Amphia Premature Infant Pain Study; Breast Milk vs Sucrose
Brief Summary: Last thirty years, many research was performed concerning pain in the newborn. These investigations showed us the negative effects of pain in the neonatal period. Our research concerns the choice of analgesics for the premature newborn during a heel lance. Newborns with a gestational age of 32-37 weeks are randomly assigned over three groups. They can receive breastfeeding, during the heel lance, a bottle with supplemental breast milk or sucrose.

The primary objective of the Amphia Premature Infant Pain study, is to investigate whether there is a difference in PIPP-scores in premature newborns who undergo a heel lance, receiving breast milk or sucrose. Our hypothesis is that the PIPP-score will be lower in newborns receiving breast milk compared to sucrose. And the investigators presume that breast feeding has the same analgesic effect as giving supplemental breast milk.


Options:
A: Arm Label: sucrose; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: supplemental breast milk; Type: ACTIVE_COMPARATOR; Interventions: Other: supplemental breast milk | Arm Label: Breast feeding; Type: ACTIVE_COMPARATOR; Interventions: Other: breast feeding | Intervention Type: OTHER; Name: breast feeding; Assigned to Arm(s): Breast feeding | Intervention Type: OTHER; Name: supplemental breast milk; Assigned to Arm(s): supplemental breast milk | Intervention Type: OTHER; Name: sucrose; Assigned to Arm(s): sucrose
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sucrose 24% oral solution | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: sterile water | Intervention Type: DRUG; Name: sucrose 24% oral solution; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sterile water; Assigned to Arm(s): 2
C: Arm Label: Kangaroo Mother Care; Type: EXPERIMENTAL; Interventions: Behavioral: Kangaroo Mother Care | Arm Label: Sucrose; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Sucrose | Arm Label: Combination Kangaroo Mother Care and Sucrose; Type: EXPERIMENTAL; Interventions: Behavioral: Kangaroo Mother Care, Dietary Supplement: Sucrose | Intervention Type: BEHAVIORAL; Name: Kangaroo Mother Care; Assigned to Arm(s): Combination Kangaroo Mother Care and Sucrose, Kangaroo Mother Care | Intervention Type: DIETARY_SUPPLEMENT; Name: Sucrose; Assigned to Arm(s): Combination Kangaroo Mother Care and Sucrose, Sucrose
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: N2O | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: oxygen | Intervention Type: OTHER; Name: N2O; Assigned to Arm(s): A | Intervention Type: OTHER; Name: oxygen; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Brief Summary: The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.


Options:
A: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: ActiveTreatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): ActiveTreatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
B: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A
C: Arm Label: KHK4827 70mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 140mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 210mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: Placebo SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: KHK4827; Assigned to Arm(s): KHK4827 140mg SC, KHK4827 210mg SC, KHK4827 70mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo SC
D: Arm Label: Etanercept; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Brief Summary: The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.


Options:
A: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab, Drug: placebo | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 140 mg brodalumab, 210 mg brodalumab, placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 140 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 140 mg SC | Arm Label: 350 mg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: 350 mg SC | Arm Label: 700 mg IV; Type: EXPERIMENTAL; Interventions: Drug: 700 mg IV | Intervention Type: DRUG; Name: 700 mg IV; Assigned to Arm(s): 700 mg IV | Intervention Type: DRUG; Name: 350 mg SC; Assigned to Arm(s): 350 mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 140 mg SC; Assigned to Arm(s): 140 mg SC
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
D: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: ActiveTreatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): ActiveTreatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Brief Summary: The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.


Options:
A: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: ActiveTreatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): ActiveTreatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
B: Arm Label: Secukinumab (AIN457) 75 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 150 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 300 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Placebo s.c.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Secukinumab (AIN457), Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab (AIN457); Assigned to Arm(s): Placebo s.c., Secukinumab (AIN457) 150 mg s.c., Secukinumab (AIN457) 300 mg s.c., Secukinumab (AIN457) 75 mg s.c. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c.
C: Arm Label: Apremilast; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo, Drug: Placebo-Apremilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Placebo-Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Apremilast, Placebo | Intervention Type: DRUG; Name: Placebo-Apremilast; Assigned to Arm(s): Apremilast, Placebo
D: Arm Label: Single-Arm, open-label extension trial; Type: OTHER; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Single-Arm, open-label extension trial

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Brief Summary: The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.


Options:
A: Arm Label: 0.25 mg VPD-737; Type: EXPERIMENTAL; Interventions: Drug: VPD-737 | Arm Label: 1 mg VPD-737; Type: EXPERIMENTAL; Interventions: Drug: VPD-737 | Arm Label: 5 mg VPD-737; Type: EXPERIMENTAL; Interventions: Drug: VPD-737 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VPD-737; Assigned to Arm(s): 0.25 mg VPD-737, 1 mg VPD-737, 5 mg VPD-737 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: cooling compound (ph5 Eucerin) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Device: cooling compound (ph5 Eucerin) | Intervention Type: DEVICE; Name: cooling compound (ph5 Eucerin); Assigned to Arm(s): 1, 2
C: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: ActiveTreatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): ActiveTreatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
D: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment

Answer: C